Totonchi Hamidreza, Rezaei Ramazan, Noori Shokoofe, Azarpira Negar, Mokarram Pooneh, Imani Danyal
Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Science, Tehran, Iran.
Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Endocr Metab Immune Disord Drug Targets. 2021;21(5):943-955. doi: 10.2174/1871530320666200805101302.
Several studies have assessed the association between the vitamin D receptor (VDR) polymorphism and the risk of metabolic syndrome (MetS). However, the results were inconsistent and inconclusive. Therefore, we conducted a meta-analysis to clarify the exact association between the vitamin D receptor (VDR) polymorphisms and the risk of MetS.
All accessible studies reporting the association between the FokI (rs2228570) or/and TaqI (rs731236) or/and BsmI (rs1544410) or/and ApaI (rs7975232 polymorphisms of the Vitamin D Receptor and susceptibility to MetS published prior to February 2019 were systematically searched in Web of Science, Scopus, and PubMed. After that, Odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were estimated to evaluate the strength of the association in five genetic models.
A total of 9 articles based on four gene variations, and comprising 3348 participants with 1779 metabolic syndrome patients were included. The overall results suggested a significant association between BsmI (rs1544410) polymorphism and MetS susceptibility in recessive model (OR, 0.72, 95% CI, 0.55-0.95, fixed effect model), allelic model (OR, 0.83, 95% CI, 0.72-0.95, fixed effect model), and bb vs BB (OR, 0.65, 95% CI, 0.46-0.93, fixed effect). However, no significant association was identified between TaqI (rs731236) polymorphism, ApaI (rs7975232) polymorphism, and FokI (rs2228570) polymorphism and MetS.
This meta-analysis suggested an association between the BsmI (rs1544410) polymorphism and MetS. Indeed, BsmI (rs1544410) acts as a protective factor in the MetS. As a result, the VDR gene could be regarded as a promising pharmacological and physiological target in the prevention or treatment of the MetS.
多项研究评估了维生素D受体（VDR）基因多态性与代谢综合征（MetS）风险之间的关联。然而，结果并不一致且尚无定论。因此，我们进行了一项荟萃分析，以阐明维生素D受体（VDR）基因多态性与MetS风险之间的确切关联。
在Web of Science、Scopus和PubMed中系统检索了2019年2月之前发表的所有报告维生素D受体的FokI（rs2228570）或/和TaqI（rs731236）或/和BsmI（rs1544410）或/和ApaI（rs7975232）基因多态性与MetS易感性之间关联的可获取研究。之后，估计比值比（OR）及其相应的95%置信区间（CI），以评估五种遗传模型中的关联强度。
共纳入9篇基于四种基因变异的文章，包括3348名参与者，其中1779例为代谢综合征患者。总体结果表明，在隐性模型（OR，0.72，95%CI，0.55 - 0.95，固定效应模型）、等位基因模型（OR，0.83，95%CI，0.72 - 0.95，固定效应模型）以及bb与BB比较（OR，0.65，95%CI，0.46 - 0.93，固定效应）中，BsmI（rs1544410）基因多态性与MetS易感性之间存在显著关联。然而，未发现TaqI（rs731236）基因多态性、ApaI（rs7975232）基因多态性和FokI（rs2228570）基因多态性与MetS之间存在显著关联。
这项荟萃分析表明BsmI（rs1544410）基因多态性与MetS之间存在关联。实际上，BsmI（rs1544410）是MetS的一个保护因素。因此，VDR基因可被视为预防或治疗MetS的一个有前景的药理学和生理学靶点。
